Quick Answer
Greenwich LifeSciences, Inc. reported Earnings Per Share Diluted of $1.21 (loss) per share for the year ending 2024.
- Greenwich LifeSciences, Inc. showed a decrease of -75.4% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Greenwich LifeSciences, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.06 (loss) per share | Q3 2022: $0.18 (loss) per share | Q1 2023: $0.17 (loss) per share | Q2 2023: $0.13 (loss) per share | Q3 2023: $0.19 (loss) per share | Q1 2024: $0.19 (loss) per share | Q2 2024: $0.20 (loss) per share | Q3 2024: $0.20 (loss) per share | Q1 2025: $0.25 (loss) per share | Q2 2025: $0.30 (loss) per share | Q3 2025: $0.30 (loss) per share.
- Over the full 3 years of available data (2022 to 2024), Greenwich LifeSciences, Inc.'s Earnings Per Share Diluted has declined by 98.4%.
- Historical annual values: Fiscal year 2024: $1.21 (loss) per share | Fiscal year 2023: $0.69 (loss) per share | Fiscal year 2022: $0.61 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: